TrialEuropean urology oncology2020
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.
Guru P Sonpavde et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papercites it